CYTADREN
LOE ApproachingNDAORALTABLETPriority Review
Approved
Oct 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYTADREN is an oral small-molecule tablet approved in 1980 by Novartis. The specific indication and mechanism of action are not publicly detailed in available data. This legacy product operates in a mature market segment with established clinical utility.
LOE Approaching
Loss of exclusivity is imminent, signaling potential team reductions and transition focus toward pipeline or lifecycle management activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's mature, stable state with minimal hiring. Professionals assigned to CYTADREN should prepare for role transitions or internal redeployment as LOE approaches.
Brand ManagerMarket Access Manager
Worked on CYTADREN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.